Health Care & Life Sciences » Biotechnology | Alder BioPharmaceuticals Inc.

Alder BioPharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Alder BioPharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
SPDR S&P Biotech ETF
2,346,949
3.44%
6,039
0.73%
09/06/2018
BB Biotech AG
2,266,008
3.32%
0
0.99%
03/31/2018
T Rowe Price Health Sciences Fund
1,486,464
2.18%
626,564
0.21%
06/30/2018
Vanguard Total Stock Market Index Fund
1,460,508
2.14%
0
0%
07/31/2018
Vanguard Small Cap Index Fund
1,448,476
2.12%
18,427
0.03%
07/31/2018
iShares Russell 2000 ETF
1,219,396
1.79%
-651
0.05%
09/06/2018
Fidelity Select Biotechnology Portfolio
1,181,295
1.73%
0
0.23%
07/31/2018
Goldman Sachs Small/Mid Cap Growth Fund
897,944
1.32%
0
0.66%
06/30/2018
Vanguard Small Cap Growth Index Fund
828,690
1.21%
12,439
0.06%
07/31/2018
Vanguard Extended Market Index Fund
792,789
1.15%
0
0.02%
07/31/2018

About Alder BioPharmaceuticals

View Profile
Address
11804 North Creek Parkway South
Bothell Washington 98011
United States
Employees -
Website http://www.alderbio.com
Updated 07/08/2019
Alder Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, which discovers, develops, and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.